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Background
Patients with severe allergic asthma (SAA) are often
inadequately controlled despite available treatments
including high-dose inhaled corticosteroids and long-
acting b2-agonists. Use of oral corticosteroids (OCS) in
SAA patients may not achieve full asthma control, and
leads to significant long-term side effects. Omalizumab is
a recombinant humanized monoclonal anti-immunoglo-
bulin E (IgE) antibody approved in the European Union
as an add-on therapy for patients with SAA. In clinical
studies, omalizumab has been shown to reduce OCS use.
Here we report the effect of omalizumab treatment on
OCS maintenance use for up to 24 months in patients
with SAA in the real-world eXpeRience registry.
Methods
eXpeRience was a 2-year, multicentre, non-interventional,
single-arm, observational registry initiated to collect data
from patients receiving omalizumab for uncontrolled SAA.
Data were collected on OCS maintenance use at baseline,
Month 12, and Month 24. Parameters assessed were inci-
dence of OCS maintenance use, total daily OCS dose and
change from baseline, and time to reduction in OCS dose
or stopping therapy.
Results
At Month 24, 49% of the patients on OCS had discon-
tinued their use and 20% had reduced their OCS dosage,
this was incremental from Month 12. OCS maintenance
use at baseline, Month 12 and Month 24 is summarized
in Table 1.
Conclusion
Omalizumab reduced the need for maintenance OCS use
in patients with severe allergic (IgE-mediated) asthma in
a real-world setting. Reduction in OCS maintenance use
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Table 1
Baseline N=916 12 months N=734 24 months N=643
Patients on OCS maintenance monotherapy, n (%) 262 (28.6) 118 (16.1) 91 (14.2)
Mean (SD) total daily OCS dose*, mg 15.49 (14.01)a 7.68 (10.94)b 5.77 (8.89)c
Mean (SD) reduction from baseline in total daily dose, mg - 7.89 (13.77)b 9.95 (15.58)c
Patients with alteration in total OCS dose, n (%)
• discontinuation - 77 (40.7)b 82 (48.8)c
• reduction - 31 (16.4)b 34 (20.2)c
• no change - 76 (40.2)b 48 (28.6)c
• increased - 5 (2.6)b 4 (2.4)c
Mean (SD) time to either reduction or discontinuation of OCS, days - 198.5 (114.29)d 291.2 (210.86)e
* OCS dose was reported in prednisolone equivalent dose as mg per day. OCS – oral corticosteroid; SD – standard deviation; n – number of patients who
received OCS at baseline and who provided OCS information at 12 months and 24 months (an=246; bn=189; cn=168; dn=108; en=116).
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may reflect better asthma control and decreases the risk
of long-term morbidity of corticosteroid exposure.
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